RLYB (Rallybio) Utang jangka cendhak marang modal

The price chart for Rallybio Corporation (RLYB) demonstrates the 0.00 indicator. Rallybio Corporation is implementing software robots and automated screening to accelerate the analysis of medical data. The business relies on partnerships with global laboratories to create antibodies for fetal protection. US-based production facilities are focused on innovative therapies for severe neonatal blood pathologies, which have been validated by successful tests.
Rincian analitis perusahaan Rallybio Corporation

Complex FDA clinical trials for Rallybio Corporation (RLYB) drugs require significant operating expenses, making the company sensitive to the cost of borrowed capital. This indicator measures the share of short-term liabilities within the equity structure, allowing for an assessment of liquidity risk and dependence on external financing through the ratio of current loans to equity.